Darya K. Bolyakina

Darya K. Bolyakina

Auto-generated profile, based on publicly available information

Darya K. Bolyakina

National Research Center Institute of Immunology FMBA of Russia Moscow Russian Federation

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NSNadezhda N. Shershakova
Nadezhda N. Shershakova
EBElena Baraboshkina
Elena Baraboshkina
DKDmitry Khochenkov
Dmitry Khochenkov
ETEvgeny Turetskiy
Evgeny Turetskiy
ANAlexandra Nikonova
Alexandra Nikonova
MKMusa Khaitov
Musa Khaitov
Hair loss (alopecia) is a common disorder caused by an interruption in the body’s cycle of hair production. This pathology negatively affects the psychoemotional state of patients and significantly reduces their quality of life. The currently available medical treatments (including minoxidil therapy) are effective in arresting the progression of the disease; however, they allow only partial regrowth of hair at best. A significant clinical result occurs only with regular drug use. There is still great interest in finding new drugs for the treatment of alopecia. In this study, we aimed to examine the effect of an aqueous dispersion of unmodified fullerene C60 (ADF) on hair growth. ADF, produced by a unique technology, is biocompatible and non-toxic. Nu/nu mice were subcutaneously injected (2 μg/animal) every two days for a period of 11 days with ADF and, for control purposes, with phosphate-buffered saline (PBS). It was shown that ADF stimulated hair growth. Histological analysis of the nu/nu mice skin areas showed that animals treated with ADF had significantly more (about twice as many) hair follicles in the anagen phase compared to mice treated with PBS. The effect on hair growth persisted even after discontinuation of ADF administration. Analysis of gene expression demonstrated that ADF affected the Wnt-signaling pathway, increased the expression of the Wnt10b (wingless-type Mouse Mammary Tumor Virus integration site family, member 10B) factor, angiogenetic factors, and downregulated tumor necrosis factor-alpha levels. We propose that the mechanism of ADF action is likely related to its ability to attract macrophages to the hair follicle microenvironment and promote their polarization to the M2 phenotype. In addition, using molecular modeling, we tried to substantiate our hypothesis about the interaction of ADF with the adenosine A2A receptor, which may cause a decrease in tumor necrosis factor-alpha production. Thus, ADF may become a promising drug for the development of new approaches to the treatment of alopecia associated with immune disorders.

1 January 2025 in Immunologiya
Verified
Journal Article
Open access
AGA.A. Galkina
A.A. Galkina
NSNadezhda N. Shershakova
Nadezhda N. Shershakova
MKM.V. Khodzhava
M.V. Khodzhava
DBD.K. Bolyakina
D.K. Bolyakina
AGA.K. Golomidova
A.K. Golomidova
MKM.R. Khaitov
M.R. Khaitov
Создание ранозаживляющих препаратов на основе антибактериальных катионных пептидов и фуллерена C60

4 September 2026 in Allergy
Verified
Journal Article
Open access
PDF file
MKMusa R. Khaitov
Musa R. Khaitov
MBMaria Byazrova
Maria Byazrova
ESEvgenii V. Smolnikov
Evgenii V. Smolnikov
VTVladislav N. Turenko
Vladislav N. Turenko
VSValery Smirnov
Valery Smirnov
VSVeronica I. Skvortsova
Veronica I. Skvortsova
Background: We have recently reported the preclinical characterization of a recombinant birch pollen allergy vaccine based on a fusion protein, AB ‐ PreS , consisting of allergen‐derived peptides fused to the hepatitis B virus ( HBV )‐derived PreS surface protein as immunological carrier. Objective: To investigate in a clinical study the usefulness of the AB ‐ PreS vaccine, termed GNR ‐127, for allergen‐specific immunotherapy of birch pollen allergy. Methods: Stage 1 of the study, an open‐label Phase I study, determined among three doses (20 μg: n = 6; 40 μg: n = 6; 80 μg: n = 6) administered as Aluminum‐hydroxide‐adsorbed vaccines subcutaneously five times in monthly intervals, the highest tolerated doses. In the following Stage 2, randomized patients (placebo: n = 45; 40 μg: n = 43; 80 μg: n = 44) received in a single‐blind, placebo‐controlled Phase II study monthly up to five pre‐seasonal injections. Safety monitoring followed the Medical Dictionary for Regulatory Activities (MedDRA); efficacy parameters were determined according to the European Academy for Allergy and Clinical Immunology ( EAACI ) guidelines; allergen‐specific antibodies and basophil sensitivity were determined by ELISA and basophil activation testing, respectively. Results: A dose‐dependent reduction of the combined symptom medication score ( CSMS ) (40 μg: 17.41%; 80 μg: 24.13%) over placebo was observed which was significant for the 80 μg group and accompanied by the strongest induction of Bet v 1‐specific IgG (median 20‐fold increase) and a blunting of the seasonally boosted IgE response and basophil sensitivity. The vaccine showed an acceptable safety profile despite high administered doses. Conclusion: A pre‐seasonal course of 5 monthly injections of GNR ‐127 80 μg improved symptoms of birch pollen allergy accompanied by a robust Bet v 1‐specific IgG response, paving the road for a Phase III efficacy study. Trial Registration: ClinicalTrials.gov (Identifier: NCT07155499)

3 June 2025 in Russian Journal of Allergy
Verified
Journal Article
Closed access
PDF file
EKElena V. Kovaleva
Elena V. Kovaleva
YIYulia V. Ivanova
Yulia V. Ivanova
NONikolay M. Onatsky
Nikolay M. Onatsky
VSVitaliia A. Shangaraeva
Vitaliia A. Shangaraeva
DGDenis S. Gorshenin
Denis S. Gorshenin
БКБолякина Дарья Константиновна
Болякина Дарья Константиновна
BACKGROUND: The incidence of food allergy in adults and children is very high. The key approach in the therapy of food allergy can be quality drug selection. New synthetic derivatives of fullerene, a high-tech hydrocarbon, can become such drugs. A unique biocompatible method for obtaining a stable aqueous dispersion of fullerene C60 (ADF-C60) as the main component for drugs for the treatment of allergic diseases has been developed. In this article, reproductive toxicity of the drug ADF-C60, currently in preclinical safety studies, was studied in female white outbred rats. Due to its properties, the ADF-C60 is promising for treatment of food allergy and can presumably be used during pregnancy. AIM: Preclinical study of reproductive toxicity of an ADF-C60 in the antenatal and postnatal periods of rat offspring development with oral administration to the mother generation during pregnancy. MATERIALS AND METHODS: Female rats were orally administered the ADF-C60 in 1-, 5-, and 50-fold therapeutic doses recommended for humans during the whole pregnancy. The general parameters of embryotoxic and teratogenic effects of the ADF-C60 before and after birth were studied. RESULTS: No evidence of embryotoxic and teratogenic effects of the ADF-C60 was found during the study of gestational parameters and general fetuses development. No adverse effects of the ADF-C60 were revealed during observation of postnatal development of offspring. CONCLUSION: ADF-C60 for the treatment of food allergy has no reproductive toxicity at doses up to 50 times higher than the therapeutic dose. After the conducted experiments it is possible to assume a significant probability of using the ADF-C60 during pregnancy, but additional preclinical and clinical studies are required to substantiate the obtained conclusion.

1 January 2025 in Immunologiya
Verified
Journal Article
Open access
DBD.K. Bolyakina
D.K. Bolyakina
OKOlesya Koloskova
Olesya Koloskova
NSNadezhda N. Shershakova
Nadezhda N. Shershakova
GGG.O. Gudima
G.O. Gudima
DKDmitry Kudlay
Dmitry Kudlay
MKM.R. Khaitov
M.R. Khaitov
Современные подходы к моделированию экспериментальной меланомы на мышах in vivo

1 January 2026 in Immunologiya
Verified
Journal Article
Closed access
DGD.S. Gorshenin
D.S. Gorshenin
Yury V. ZhernovYury V. Zhernov
Yury V. Zhernov
VTVladimir Tikhonov
Vladimir Tikhonov
AGA.A. Galkina
A.A. Galkina
DBD.K. Bolyakina
D.K. Bolyakina
MKM.R. Khaitov
M.R. Khaitov